Brief: Corbus Pharmaceuticals Says CRB-701 Was Well-Tolerated In First-In-Human Study

Corbus Pharmaceuticals Holdings

26/01/2024 13:07

Jan 26 (Reuters) - Corbus Pharmaceuticals Holdings Inc
 CRBP.O :
    * CRB-701 (SYS6002) A NEXT GENERATION NECTIN-4 TARGETING
ANTIBODY
DRUG CONJUGATE DEMONSTRATES ENCOURAGING SAFETY AND EFFICACY IN
PATIENTS WITH NECTIN-4 POSITIVE TUMORS IN FIRST-IN-HUMAN STUDY
PRESENTED AT ASCO-GU 2024
    * CORBUS PHARMACEUTICALS HOLDINGS INC: Q3W SCHEDULE OF
CRB-701
(SYS6002) DEMONSTRATES A 43% ORR AND 71% DCR AT PREDICTED
THERAPEUTICALLY RELEVANT DOSES
    * CORBUS: NO DOSE LIMITING TOXICITIES (DLTS) HAVE BEEN
OBSERVED
TO-DATE UP TO 3.6 MG/KG (COHORT 6) WITH FURTHER ESCALATION AT
4.5 MG/KG ONGOING
    * CORBUS PHARMACEUTICALS HOLDINGS INC: NO CASES OF
PERIPHERAL
NEUROPATHY OR SKIN RASH HAVE BEEN OBSERVED TO DATE
    * CORBUS PHARMACEUTICALS HOLDINGS INC: COHORT 6 IS FIRST
COHORT
SELECTED FOR DOSE EXPANSION
    * CORBUS: ALL ASSESSABLE NECTIN-4 POSITIVE STUDY
PARTICIPANTS WITH
MUC & CERVICAL CANCER TREATED AT/ABOVE DOSE DEMONSTRATED SOME
LEVEL OF DISEASE CONTROL
    * CORBUS PHARMACEUTICALS HOLDINGS INC: CRB-701 WAS
WELL-TOLERATED
WITH MAJORITY OF ADVERSE EVENTS BEING GRADE ONE OR TWO AND
REVERSIBLE
    * CORBUS PHARMACEUTICALS HOLDINGS INC: LOOKING FORWARD TO
COMMENCING OUR CLINICAL STUDY IN US IN Q1 2024 UNDER AN ALREADY
OPEN IND
    * CORBUS PHARMACEUTICALS HOLDINGS INC: THERE HAVE BEEN NO
DOSE
DISCONTINUATIONS OR REDUCTIONS IN STUDY TO DATE

Source text for Eikon:  ID:nGNXZjdbQ 
Further company coverage:  CRBP.O 

 ((reuters.briefs@thomsonreuters.com;))